DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Disease, Chronic Obstructive

Intervention: Atrovent® - inhalets (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

Clinical Details

Official title: Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Change in overall severity of the clinical picture

Secondary outcome:

Assessment of efficacy by investigator on a 4-point scale

Assessment of efficacy by patient on a 4-point scale

Number of patients with adverse drug reactions

Assessment of tolerability by investigator on a 4-point scale

Assessment of tolerability by patient on a 4-point scale

Eligibility

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients of both genders older than 40 years, who suffer from Chronic Obstructive

Pulmonary Disease

- Only patients who have not been treated with Atrovent® within the last year are to be

considered for inclusion Exclusion Criteria:

- Contraindications listed in the Instructions for Use/Summary of Product

Characteristics for Atrovent® metered dose inhaler

Locations and Contacts

Additional Information

Starting date: February 2001
Last updated: September 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017